PsychoGenics Appoints John McCall, Ph.D. as Newest Member to its Scientific Advisory Board (SAB) : This Appointment Reflects the Company's Expansion into Drug Discovery and Development

Share Article

PsychoGenics Inc., announces the appointment of John McCall, Ph.D., as a member of its Scientific Advisory Board, reflecting the company’s growth in the areas of Drug Discovery and Development.

News Image
I look forward to my contribution as an advisor to PsychoGenics, a stimulating company with a unique and innovative approach to drug discovery

Dr. McCall has over thirty years experience in the pharmaceutical industry including senior positions held at Pfizer, as Senior Vice President of Pfizer Global Research, Site Head for Pfizer Chicago, for Pharmacia and Upjohn as Vice President of Global Discovery Chemistry, Global Vice President Discovery Chemistry, and for Upjohn as Head of CNS and Head of Chemistry. Dr. McCall is currently the President of PharMac LLC, providing consulting services for drug discovery, project management, project evaluation, and research organization, to the pharmaceutical industry. He chairs the Spinal Muscular Atrophy project for NINDS and is a partner in the Apjohn Group.

"I look forward to my contribution as an advisor to PsychoGenics, a stimulating company with a unique and innovative approach to drug discovery", commented Dr. McCall.

"We are extremely excited about John's addition to our SAB", explained Dr Eric Nestler, Scientific co-founder and Chairman of PsychoGenics' Scientific Advisory Board, "John's considerable experience and expertise in drug discovery and development will be of great value to PsychoGenics as it expands its internal and partnered drug discovery programs".

PsychoGenics' SAB includes academic leaders in their respective fields: Dr Eric Nestler, scientific co-founder of PsychoGenics, who recently returned to New York City as Chair of Neuroscience and Director of the Brain Institute at the Mount Sinai School of Medicine; Dr Paul Greengard, awarded the Nobel Prize for Medicine and Physiology in 2000, and the Vincent Astor Professor and Head of the Laboratory of Molecular and Cellular Neuroscience at Rockefeller University; Dr Ronald Duman, Professor of the Departments of Psychiatry and Pharmacology at Yale University School of Medicine; Dr Rene Hen, Professor of Pharmacology at the Columbia University Center of Neurobiology and Behavior; Dr George Koob, Director of the Division of Psychopharmacology at Scripps Research Institute; Dr Richard Paylor, Professor of the Department of Molecular and Human Genetics at Baylor College of Medicine; and Dr Berend Olivier, Director or PsychoGenics' European Operation and Chairman and Professor of the Department of Psychopharmacology at Utrecht University.

About PsychoGenics:

PsychoGenics is a leader in preclinical behavioral neurobiology and a provider of customized and innovative solutions for central nervous system (CNS) drug discovery. PsychoGenics works with pharmaceutical and biotechnology companies, academic institutions and not-for-profit research foundations to address such major neurological disorders as: ALS, Huntington's Disease, anxiety, cognitive impairment, depression, psychosis/schizophrenia and SMA. PsychoGenics supports the understanding and treatment of CNS disorders by offering an extensive range of established and customized validated in vivo behavioral tests, behavioral pharmacology, phenotyping, bioinformatics, microdialysis and radiotelemetry.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

David Pushett
Visit website